Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 76 entries
View as:

Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency

Phase: N/A Priority: Normal
NCT ID: NCT01916993 Org: User:
Start: 08/31/13 End: 12/31/13 Due: 12/31/14

A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.

Phase: N/A Priority: Normal
NCT ID: NCT03496870 Org: User:
Start: 02/08/18 End: 07/02/18 Due: 07/02/19

Study to Determine D-amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After Single-dose Oral Administration

Phase: N/A Priority: Normal
NCT ID: NCT02716987 Org: User:
Start: 03/21/16 End: 08/30/16 Due: 08/30/17

Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00039052 Org: User:
Start: 01/31/02 End: 07/31/08 Due: 07/31/09

Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada

Phase: N/A Priority: Normal
NCT ID: NCT06312189 Org: User:
Start: 04/24/24 End: 04/30/26 Due: 04/30/27

A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT02566759 Org: User:
Start: 09/23/15 End: 07/12/16 Due: 07/12/17

NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)

Phase: N/A Priority: Normal
NCT ID: NCT01688037 Org: User:
Start: 09/30/12 End: 10/31/13 Due: 10/31/14

Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT03325010 Org: User:
Start: 10/05/17 End: 11/16/18 Due: 11/16/19

TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT02561156 Org: User:
Start: 08/26/15 End: 09/23/17 Due: 09/23/18

Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT02256475 Org: User:
Start: 09/30/14 End: 12/31/15 Due: 12/31/16

NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Phase: N/A Priority: Normal
NCT ID: NCT06911112 Org: User:
Start: 03/31/25 End: 07/31/27 Due: 07/31/28

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

Phase: N/A Priority: Normal
NCT ID: NCT02748694 Org: User:
Start: 05/09/16 End: 09/22/19 Due: 09/22/20

Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia

Phase: N/A Priority: Normal
NCT ID: NCT02405091 Org: User:
Start: 03/31/15 End: 03/31/17 Due: 03/31/18

Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD

Phase: N/A Priority: Normal
NCT ID: NCT05165394 Org: User:
Start: 11/30/21 End: 09/13/23 Due: 09/13/24

A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT03382639 Org: User:
Start: 01/04/18 End: 01/12/21 Due: 01/12/22

Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT03732534 Org: User:
Start: 10/17/18 End: 02/18/19 Due: 02/18/20

Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia

Phase: N/A Priority: Normal
NCT ID: NCT02349503 Org: User:
Start: 02/28/15 End: 10/31/15 Due: 10/31/16

A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia

Phase: N/A Priority: Normal
NCT ID: NCT02274558 Org: User:
Start: 10/31/14 End: 07/31/16 Due: 07/31/17

NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia

Phase: N/A Priority: Normal
NCT ID: NCT01733121 Org: User:
Start: 12/31/12 End: 12/31/13 Due: 12/31/14

A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder

Phase: N/A Priority: Normal
NCT ID: NCT06267846 Org: User:
Start: 03/20/24 End: 12/31/25 Due: 12/31/26

A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT03706469 Org: User:
Start: 10/18/18 End: 12/22/18 Due: 12/22/19

A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures

Phase: N/A Priority: Normal
NCT ID: NCT05159908 Org: User:
Start: 11/08/21 End: 08/21/23 Due: 08/21/24

Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia

Phase: N/A Priority: Normal
NCT ID: NCT04490915 Org: User:
Start: 12/16/20 End: 08/31/27 Due: 08/31/28

Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia

Phase: N/A Priority: Normal
NCT ID: NCT05859698 Org: User:
Start: 05/25/23 End: 12/27/24 Due: 12/27/25

Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)

Phase: N/A Priority: Normal
NCT ID: NCT05203341 Org: User:
Start: 02/21/22 End: 02/21/24 Due: 02/21/25